Literature DB >> 22212672

Brentuximab vedotin.

Anas Younes, Uma Yasothan, Peter Kirkpatrick.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22212672     DOI： 10.1038/nrd3629

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  9 in total

Review 1.  CD30-targeted antibody therapy.

Authors:  Anas Younes
Journal:  Curr Opin Oncol       Date:  2011-11       Impact factor: 3.645

Review 2.  Antibody-drug conjugates: targeted drug delivery for cancer.

Authors:  Stephen C Alley; Nicole M Okeley; Peter D Senter
Journal:  Curr Opin Chem Biol       Date:  2010-07-17       Impact factor: 8.822

3.  Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor.

Authors:  Martin R Weihrauch; Oliver Manzke; Marc Beyer; Heinz Haverkamp; Volker Diehl; Heribert Bohlen; Juergen Wolf; Joachim L Schultze
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

4.  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Authors:  Anas Younes; Nancy L Bartlett; John P Leonard; Dana A Kennedy; Carmel M Lynch; Eric L Sievers; Andres Forero-Torres
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

5.  cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Authors:  Joseph A Francisco; Charles G Cerveny; Damon L Meyer; Bruce J Mixan; Kerry Klussman; Dana F Chace; Starr X Rejniak; Kristine A Gordon; Ron DeBlanc; Brian E Toki; Che-Leung Law; Svetlana O Doronina; Clay B Siegall; Peter D Senter; Alan F Wahl
Journal:  Blood       Date:  2003-04-24       Impact factor: 22.113

6.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Authors:  Svetlana O Doronina; Brian E Toki; Michael Y Torgov; Brian A Mendelsohn; Charles G Cerveny; Dana F Chace; Ron L DeBlanc; R Patrick Gearing; Tim D Bovee; Clay B Siegall; Joseph A Francisco; Alan F Wahl; Damon L Meyer; Peter D Senter
Journal:  Nat Biotechnol       Date:  2003-06-01       Impact factor: 54.908

7.  The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.

Authors:  Alan F Wahl; Kerry Klussman; Jennifer D Thompson; Judy H Chen; Leigh V Francisco; Grant Risdon; Dana F Chace; Clay B Siegall; Joseph A Francisco
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

8.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

Authors:  Andrea Gallamini; Martin Hutchings; Luigi Rigacci; Lena Specht; Francesco Merli; Mads Hansen; Caterina Patti; Annika Loft; Francesco Di Raimondo; Francesco D'Amore; Alberto Biggi; Umberto Vitolo; Caterina Stelitano; Rosario Sancetta; Livio Trentin; Stefano Luminari; Emilio Iannitto; Simonetta Viviani; Ivana Pierri; Alessandro Levis
Journal:  J Clin Oncol       Date:  2007-07-23       Impact factor: 44.544

9.  Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

Authors:  N L Bartlett; D Niedzwiecki; J L Johnson; J W Friedberg; K B Johnson; K van Besien; A D Zelenetz; B D Cheson; G P Canellos
Journal:  Ann Oncol       Date:  2007-04-10       Impact factor: 32.976
  9 in total
  45 in total

Review 1.  Optimising the delivery of tubulin targeting agents through antibody conjugation.

Authors:  Gary D Stack; John J Walsh
Journal:  Pharm Res       Date:  2012-07-10       Impact factor: 4.200

2.  The melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanoma.

Authors:  Youjun Chen; Cecile Chalouni; Christine Tan; Robyn Clark; Rayna Venook; Rachana Ohri; Helga Raab; Ron Firestein; William Mallet; Paul Polakis
Journal:  J Biol Chem       Date:  2012-05-21       Impact factor: 5.157

Review 3.  Microbial natural products: molecular blueprints for antitumor drugs.

Authors:  Lesley-Ann Giddings; David J Newman
Journal:  J Ind Microbiol Biotechnol       Date:  2013-09-03       Impact factor: 3.346

4.  Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma.

Authors:  Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

5.  First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.

Authors:  Alexander N Starodub; Allyson J Ocean; Manish A Shah; Michael J Guarino; Vincent J Picozzi; Linda T Vahdat; Sajeve S Thomas; Serengulam V Govindan; Pius P Maliakal; William A Wegener; Steven A Hamburger; Robert M Sharkey; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2015-05-05       Impact factor: 12.531

6.  Molecular design and synthesis of self-assembling camptothecin drug amphiphiles.

Authors:  Andrew G Cheetham; Yi-An Lin; Ran Lin; Honggang Cui
Journal:  Acta Pharmacol Sin       Date:  2017-03-06       Impact factor: 6.150

Review 7.  Strategies and challenges for the next generation of antibody-drug conjugates.

Authors:  Alain Beck; Liliane Goetsch; Charles Dumontet; Nathalie Corvaïa
Journal:  Nat Rev Drug Discov       Date:  2017-03-17       Impact factor: 84.694

Review 8.  Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics.

Authors:  Xin Xu; Yulia Vugmeyster
Journal:  AAPS J       Date:  2012-08-04       Impact factor: 4.009

9.  Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin.

Authors:  Dhaval K Shah; Nahor Haddish-Berhane; Alison Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-15       Impact factor: 2.745

10.  Single-antibody, targeted nanoparticle delivery of camptothecin.

Authors:  Han Han; Mark E Davis
Journal:  Mol Pharm       Date:  2013-05-29       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.